NASDAQ · VOR
Vor Biopharma Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for VOR: Nov 12, 2026
Vor Biopharma Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.81. The reported EPS for the same quarter last year was $-3.33.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.81 | $-0.75 | $-0.91 | 4 |
| Dec 2026 | $-0.84 | $-0.77 | $-0.94 | 5 |
| Mar 2027 | $-0.81 | $-0.74 | $-0.90 | 3 |
| Jun 2027 | $-0.30 | $0.81 | $-0.87 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · The Motley Fool · RTTNews · Zacks- Fintel · Oct 21, 9:58 AM EDTWilliam Blair Initiates Coverage of Vor Biopharma at OutperformFintel reports that on October 21, 2026, William Blair initiated coverage of Vor Biopharma (NASDAQGS:VOR) with a Outperform recommendation. Prior to this coverage initiation, on October 20, 2026, the stock closed at $19.03. The market performance of Vor Biopharma leading up to th
- The Motley Fool · Aug 31, 5:04 AM EDTJohnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.J&J's portfolio primarily includes small biotech and medtech companies.
- RTTNews · Aug 11, 11:22 AM EDTVor Bio Advances Telitacicept Programs; Phase 3 GMG Data Expected In 1H27(RTTNews) – Vor Bio (VOR), a clinical-stage biotechnology company reported its second-quarter 2026 financial results today and provided a corporate update, with investors focusing on continued Phase 3 progress for telitacicept and a cash runway extending into early 2029.
- RTTNews · Jul 21, 11:20 PM EDTTop Biotech Gainers: WGRX Rebrands, PVLA Nears FDA Milestone, ASBP On Track For NDA Filing(RTTNews) – Today's top biotech gainers include Wellgistics following its rebranding, Femasys, which recently resolved its Nasdaq compliance issue, Vor Bio with continued progress in its Telitacicept program, and Sol-Gel Technologies as investors look ahead to key SGT-610 Phase 3
- RTTNews · Jun 12, 11:36 AM EDTWeekly Buzz: GH, LLY Gain FDA Nod; TEVA, GSK, Lead M&A Wave; ZEAL, LLY Post Strong Data(RTTNews) – This week, the biotech sector saw a surge of FDA, EU, and China approvals spanning oncology, dermatology, autoimmune and rare disease indications. Strategic acquisitions and licensing deals drove pipeline expansion, while positive clinical readouts in obesity, MASLD,
- RTTNews · Jun 8, 11:05 AM EDTVorBio: Telitacicept Wins First Approval For Sjögren's Disease In China(RTTNews) – Vor Bio (VOR) today announced that Telitacicept (developed by RemeGen) has received approval from China's NMPA for the treatment of adult patients with Sjögren's disease.
- Zacks · May 7, 9:55 AM EDTWall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to TradeThe consensus price target hints at a 124.6% upside potential for Vor Biopharma (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Zacks · Apr 20, 9:55 AM EDTDoes Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 117% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Zacks · Apr 2, 12:00 PM EDTVor Biopharma (VOR) Upgraded to Buy: Here's WhyVor Biopharma (VOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Zacks · Apr 2, 9:55 AM EDTWall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should KnowThe average of price targets set by Wall Street analysts indicates a potential upside of 107.8% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Fintel · Mar 30, 8:04 PM EDTJefferies Initiates Coverage of Vor Biopharma (VOR) with Buy RecommendationFintel reports that on March 30, 2026, Jefferies initiated coverage of Vor Biopharma (NasdaqGS:VOR) with a Buy recommendation. Analyst Price Forecast Suggests 163.65% Upside
- RTTNews · Mar 27, 10:23 AM EDTVor Bio Unveils $75 Mln Private Placement To Advance Telitacicept; Stock Up(RTTNews) – Vor Bio (VOR), a clinical-stage biotechnology company, announced on Friday that it has entered into a securities purchase agreement to sell 5.34 million shares of its common stock at a price of $14.05 per share in a private placement. The gross proceeds from the priva
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Vor Biopharma Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.